BioLamina has announced plans to open an office in the US to further fuel company growth and market expansion.
The new office will be in Boston, MA. This strategic move will help BioLamina to better support existing and new customers in the US and brings the company closer geographically to world-renowned science hubs, it states.
“Our products solve difficult problems for our customers and help them to develop new therapies. Expanding to the US is a key step in ensuring that our products can contribute as far as possible within their recognized applications, as well as for realizing other possibilities of our matrices. Establishing an office in the Boston-Cambridge area not only brings us closer to our customers but will also open new opportunities for collaboration and market openings,” says Veronica Byfield Sköld, CEO of BioLamina.
Led by Therese Kallur
The Boston office will complement the Swedish headquarters just outside Stockholm and will focus on driving new business and the development of commercial operations on American soil. Operations will start at the end of September 2022. The company will soon begin recruiting for key commercial roles in the US organization.
The expansion will be led by Dr. Therese Kallur, CSO and VP Business Development at BioLamina. Dr. Kallur has been with BioLamina since 2010 and has played a pivotal role in the company’s success. She will further strengthen the BioLamina network, initiatives and footprint in the US as she begins operating from the Boston office.
Expanding manufacturing capacity
BioLamina is experiencing a surge in demand from customers worldwide, especially within the cell therapy field. To meet this demand, BioLamina is also expanding manufacturing capacity several-fold by building a brand-new production and R&D facility and by moving into newly established office spaces adjacent to our Stockholm headquarters.